Patents by Inventor Pascal Chaux

Pascal Chaux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human Cytomegalovirus Immunogenic Composition
    Publication number: 20230277655
    Abstract: The invention relates to an immunogenic composition comprising an HCMV gH/gL/UL128/UL130/UL131 pentameric complex antigen and a TH1-inducing adjuvant. It further relates to the immunogenic composition for use as an HCMV vaccine.
    Type: Application
    Filed: December 8, 2022
    Publication date: September 7, 2023
    Inventors: Pascal Chaux, Rafaela Dumas, Jean Haensler, Sylvie Pichon, Fabienne Piras-Douce
  • Human cytomegalovirus immunogenic composition
    Patent number: 11524069
    Abstract: The invention relates to an immunogenic composition comprising an HCMV gB antigen, an HCMV gH/gL/UL128/UL130/UL131 pentameric complex antigen and a Th1-inducing adjuvant. If further relates to the immunogenic composition for use as an HCMV vaccine.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: December 13, 2022
    Assignee: Sanofi Pasteur
    Inventors: Pascal Chaux, Rafaela Dumas, Jean Haensler, Sylvie Pichon, Fabienne Piras-Douce
  • Human cytomegalovirus immunogenic composition
    Patent number: 11207403
    Abstract: The invention relates to an immunogenic composition comprising an HCMV gH/gL/UL128/UL130/UL131 pentameric complex antigen and a TH1-inducing adjuvant. It further relates to the immunogenic composition for use as an HCMV vaccine.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: December 28, 2021
    Assignee: Sanofi Pasteur
    Inventors: Pascal Chaux, Rafaela Dumas, Jean Haensler, Sylvie Pichon, Fabienne Piras-Douce
  • Human Cytomegalovirus Immunogenic Composition
    Publication number: 20210023202
    Abstract: The invention relates to an immunogenic composition comprising an HCMV gH/gL/UL128/UL130/UL131 pentameric complex antigen and a TH1-inducing adjuvant. It further relates to the immunogenic composition for use as an HCMV vaccine.
    Type: Application
    Filed: October 15, 2020
    Publication date: January 28, 2021
    Inventors: Pascal Chaux, Rafaela Dumas, Jean Haensler, Sylvie Pichon, Fabienne Piras-Douce
  • Human Cytomegalovirus Immunogenic Composition
    Publication number: 20200276301
    Abstract: The invention relates to an immunogenic composition comprising an HCMV gB antigen, an HCMV gH/gL/UL128/UL130/UL131 pentameric complex antigen and a Th1-inducing adjuvant. If further relates to the immunogenic composition for use as an HCMV vaccine.
    Type: Application
    Filed: September 11, 2018
    Publication date: September 3, 2020
    Inventors: Pascal Chaux, Rafaela Dumas, Jean Haensler, Sylvie Pichon, Fabienne Piras-Douce
  • Thermoreversible oil-in-water emulsion
    Patent number: 9504659
    Abstract: The invention relates to a thermoreversible oil-in-water emulsion comprising: a TLR4 agonist, the chemical structure of which does not comprise a sugar ring, squalene, a nonionic surfactant belonging to the polyoxyethylene alkyl ether chemical group, a hydrophilic surfactant, an aqueous solvent, and which shows immunostimulating properties.
    Type: Grant
    Filed: January 10, 2007
    Date of Patent: November 29, 2016
    Assignee: Sanofi Pasteur SA
    Inventors: Marie-Françoise Klucker, Jean Haensler, Patricia Probeck-Quelleec, Pascal Chaux
  • MAGE-A3 PEPTIDES PRESENTED BY HLA-DR1 MOLECULES
    Publication number: 20090203124
    Abstract: The invention describes HLA class II binding peptides encoded by the MAGE tumor associated genes, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of MAGE genes.
    Type: Application
    Filed: January 18, 2008
    Publication date: August 13, 2009
    Applicant: Ludwig Institute for Cancer Research
    Inventors: Yi Zhang, Pascal Chaux, Thierry Boon-Falleur, Pierre van der Bruggen
  • MAGE peptides presented by HLA class II molecules
    Patent number: 7388072
    Abstract: The invention describes HLA class II binding peptides encoded by the MAGE tumor associated genes, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of MAGE genes.
    Type: Grant
    Filed: May 23, 2003
    Date of Patent: June 17, 2008
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Yi Zhang, Pascal Chaux, Thierry Boon-Falleur, Pierre Van Der Bruggen
  • MAGE-A3 peptides presented by HLA class II molecules
    Patent number: 7371845
    Abstract: The invention describes HLA class II binding peptides encoded by the MAGE-A3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-A3 gene.
    Type: Grant
    Filed: May 23, 2006
    Date of Patent: May 13, 2008
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Yi Zhang, Pascal Chaux, Thierry Boon-Falleur, Pierre Van Der Bruggen
  • Tumor antigens and CTL clones isolated by a novel procedure
    Patent number: 7351409
    Abstract: The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for proteins of the MAGE family. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant Yersinia, recombinant Salmonella, or recombinant viruses. The present invention further relates to antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.
    Type: Grant
    Filed: January 7, 2004
    Date of Patent: April 1, 2008
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pascal Chaux, Rosalie Luiten, Nathalie Demotte, Marie-Therese Duffour, Christophe Lurquin, Catie Traversari, Vincent Stroobant, Guy R. Cornelis, Thierry Boon-Falleur, Pierre van der Bruggen, Erwin Schultz, Guy Warnier
  • Thermoreversible Oil-In-Water Emulsion
    Publication number: 20070191314
    Abstract: The invention relates to a thermoreversible oil-in-water emulsion comprising: a TLR4 agonist, the chemical structure of which does not comprise a sugar ring, squalene, a nonionic surfactant belonging to the polyoxyethylene alkyl ether chemical group, a hydrophilic surfactant, an aqueous solvent, and which shows immunostimulating properties.
    Type: Application
    Filed: January 10, 2007
    Publication date: August 16, 2007
    Applicant: SANOFI PASTEUR SA
    Inventors: Marie-Francoise Klucker, Jean Haensler, Patricia Probeck-Quelleec, Pascal Chaux
  • MAGE-3 peptides presented by HLA class II molecules
    Patent number: 7252825
    Abstract: The invention describes HLA class II binding peptides encoded by the MAGE-3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-3 gene.
    Type: Grant
    Filed: June 12, 2002
    Date of Patent: August 7, 2007
    Assignees: Ludwig Institute for Cancer Research, Vrije Universiteit Brussel
    Inventors: Pascal Chaux, Vincent Stroobant, Thierry Boon-Falleur, Pierre van der Bruggen, Kris Thielemans, Jurgen Kurthals
  • MAGE-A1 peptides presented by HLA class II molecules
    Patent number: 7157091
    Abstract: The invention provides isolated HLA DRB1*15-binding peptides consisting of the amino acid sequence set forth as SEQ ID NO:7 with 0–10 amino acids added to either or both ends of the amino acid sequence set forth as SEQ ID NO:7, and an endosomal targeting signal comprising an endosomal targeting portion of human invariant chain Ii or LAMP-1.
    Type: Grant
    Filed: June 18, 1999
    Date of Patent: January 2, 2007
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Jacques Van Snick, Bernard Lethé, Pascal Chaux, Thierry Boon-Falleur, Pierre van der Bruggen
  • MAGE-A3 peptides presented by HLA class II molecules
    Publication number: 20060211091
    Abstract: The invention describes HLA class II binding peptides encoded by the MAGE-A3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-A3 gene.
    Type: Application
    Filed: May 23, 2006
    Publication date: September 21, 2006
    Inventors: Yi Zhang, Pascal Chaux, Thierry Boon-Falleur, Pierre Bruggen
  • MAGE-A3 peptides presented by HLA class II molecules
    Patent number: 7049413
    Abstract: The invention describes HLA class II binding peptides encoded by the MAGE-A3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-A3 gene.
    Type: Grant
    Filed: May 18, 2001
    Date of Patent: May 23, 2006
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Yi Zhang, Pascal Chaux, Thierry Boon-Falleur, Pierre van der Bruggen
  • Tumor antigens and CTL clones isolated by a novel procedure
    Publication number: 20040185033
    Abstract: The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for proteins of the MAGE family. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant Yersinia, recombinant Salmonella, or recombinant viruses. The present invention further relates to antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.
    Type: Application
    Filed: January 7, 2004
    Publication date: September 23, 2004
    Inventors: Pascal Chaux, Rosalie Luiten, Nathalie Demotte, Marie-Therese Duffour, Christophe Lurquin, Catie Traversari, Vincent Stroobant, Guy R. Cornelis, Thierry Boon-Falleur, Pierre van der Bruggen, Erwin Schultz, Guy Warnier
  • MAGE peptides presented by HLA class II molecules
    Publication number: 20040077045
    Abstract: The invention describes HLA class II binding peptides encoded by the MAGE tumor associated genes, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of MAGE genes.
    Type: Application
    Filed: May 23, 2003
    Publication date: April 22, 2004
    Inventors: Yi Zhang, Pascal Chaux, Thierry Boon-Falleur, Pierre Van Der Bruggen
  • Mage-A3 peptides presented by HLA class molecules
    Patent number: 6716809
    Abstract: The invention describes HLA class II binding peptides encoded by the MAGE-A3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-A3 gene.
    Type: Grant
    Filed: September 15, 1999
    Date of Patent: April 6, 2004
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Erwin Schultz, Pascal Chaux, Jacques van Snick, Bernard Lethe, Thierry Boon-Fallaur, Pierre van der Bruggan, Vincent Stroobant, Kris Thielemans, Jurgen Corthals, Carlo Heirman
  • Tumor antigens and CTL clones isolated by a novel procedure
    Patent number: 6710172
    Abstract: The present invention relates to nucleic acid molecules encoding antigenic peptides from MAGE molecules that bind to HLA. An example of the nucleic acid molecules of the present invention is a nucleic acid molecule coding for the peptide GVYDGREHTV (SEQ ID NO: 44), which peptide binds to HLA-A2. The nucleic acid molecules and the encoded antigenic peptides are useful for diagnosing and treating various pathological conditions.
    Type: Grant
    Filed: July 30, 2001
    Date of Patent: March 23, 2004
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Pascal Chaux, Rosalie Luiten, Nathalie Demotte, Marie-Therese Duffour, Christophe Lurquin, Catie Traversari, Vincent Stroobant, Guy R. Cornelis, Thierry Boon-Falleur, Pierre van der Bruggen, Erwin Schultz, Guy Warnier
  • MAGE-3 peptides presented by HLA class ll molecules
    Publication number: 20030170792
    Abstract: The invention describes HLA class II binding peptides encoded by the MAGE-3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-3 gene.
    Type: Application
    Filed: June 12, 2002
    Publication date: September 11, 2003
    Inventors: Pascal Chaux, Vincent Stroobant, Thierry Boon-Falleur, Pierre van der Bruggen, Kris Thielemans, Jurgen Corthals